Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Utah
I thought (assumes) we’d taken on the NED’s some 18+ months ago to tie up loose ends, possibly check paperwork and legalities and hopefully find us, or secure us a deal. Unless the worlds longest NDA has been in motion for over a year, IMO they’ve delivered us nothing. Aside from a vastly increased wages bill every month.
I have every faith in Sareum’s compounds and the science, but little in any of the board. Yes, Tim is a genie in the lab, but for the last 18 months or more, all of the others appear to have been a financial drain and I doubt it can go on for much longer before the masses (us) start demanding proof of what we are paying for every month
I’ve said this several times, NG dragging his heels or not prioritising SRA737 will, before long, start potentially costing people their lives. Surely ICR/CRT can put pressure on him, given how effective it is, especially against cancers that have no known treatment at present.
I personally still think there’s more to Gileads interest in Sierra than meets the eye. Combine Remdesivir with the only available Tyk2 (with no MTD) then they may well be onto global domination in the coronavirus battle
Posted this link earlier in the week, Keytruda getting a lot of coverage at the moment in combination therapy:
https://www.dailymail.co.uk/health/article-7519901/Immunotherapy-drug-help-thousands-women-aggressive-form-breast-cancer.html
Article on MailOnline about Keytruda, interesting read too
https://www.dailymail.co.uk/health/article-7519901/Immunotherapy-drug-help-thousands-women-aggressive-form-breast-cancer.html
From 10 Sept 18, Tim doing a spot of name dropping last year...
Small-molecule drug development company Sareum Holdings said it had made the formal selection of a development candidate for a new treatment for autoimmune disease.
The candidate molecule -- SDC-1801 -- demonstrated high selectivity for TYK2 and JAK1 kinases, compelling activity in disease models of psoriasis and rheumatoid arthritis, the potential for once-daily oral dosing and a good early safety profile, the company said.
Closely-related molecules, including SAR-20347, had also shown good activity in models of inflammatory bowel disease and systemic lupus erythematosus.
'These attributes strongly support the progression of SDC-1801 into preclinical development and, pending satisfactory progress, advancement into human clinical trials, which could begin in 2020,' Sareum said.
The company said it was also completing its assessment of further dual TYK2/JAK1 inhibitors for the potential treatment of certain cancers and expected to nominate this candidate in the near future.
'TYK2 and JAK1 have emerged in recent years as important targets for new drugs with potential to treat a broad range of autoimmune diseases,'chief executive Tim Mitchell said.
'This has naturally led to some serious interest from the major pharmaceutical companies, including Pfizer, Bristol-Myers Squibb and Celgene having their own clinical and preclinical programmes in this area.
'With SDC-1801, we believe we are entering this space with a strong candidate that exhibits potentially best-in-class features.'
Apologies if already posted, SAR get a mention 2nd from last paragraph
https://quoteddata.com/2019/06/bmss-plan-dispose-otezla-increases-focus-putative-tyk2i-class/
And lets not forget JP Morgans rather conservative rating of 200p.... We could well pass that in the next few months
If Novartis do it'll have ot be something pretty spectacular. Vectura have no financial worries, income is increasing almost weekly with the new approvals in 2 European countries and it wont be long before we see more. All times high are being reached every week, and this is being picked up by more and more investors by the day. Am already thinking JPM. Morgan were being very conservative with their recent 200 p target price re-rating GLA